Gossamer Bio is trading 6.38% down at $9.25, with no clear company-specific catalyst identified. - Searches found no company-specific announcement or news on October 9, 2026, directly explaining the decline. - The latest prominent company coverage concerned analyst views published earlier in October, not a new catalyst. - The broader market and biotech sector were reportedly higher, offering no clear same-direction explanation; the move’s specific cause remains unclear from available reporting.